Fatty Acid Amide Hydrolase Inhibitor Screening Assay Kit Reference: 10005196-96 FAAH is a cytosolic serine hydrolase responsible for the degradation of fatty acid amides, including AEA. Finding inhibitors to FAAH could offer a beneficial approach toward the treatment of pain, obesity, and various neurological diseases where higher endocannabinoid activity would be beneficial. Cayman’s FAAH Inhibitor Screening Assay provides a convenient fluorescence-based method for screening FAAH inhibitors. FAAH hydrolyzes AMC-arachidonoyl amide resulting in the release of the fluorescent product, 7-amino-4-methylcoumarin (AMC). The fluorophore can be easily analyzed using an excitation wavelength between 340-360 nm and an emission wavelength between 450-465 nm.
Atherosclerosis Product Pack Reference: 10005292-1 Contains SOAT-1/ACAT-1 polyclonal antibody and blocking peptide, cholesteryl linoleate hydroperoxides, POV-PC, and PGPC
Renin Inhibitor Screening Assay Kit Reference: 10006270-96 Cayman’s Renin Inhibitor Screening Assay provides a convenient assay in a 96-well format for evaluating human renin inhibitors. The assay utilizes a renin-based synthetic peptide substrate which incorporates the fluorophore EDANS at one end and an EDAN-quenching molecule (Dabcyl) at the other end. After cleavage by renin, the peptide-EDANS product is released yielding bright fluorescence which can be easily analyzed using excitation wavelengths between 335-345 nm and emission wavelengths between 485-510 nm.